CellProtect Nordic Pharmaceuticals AB (CPNP) develops new cell-based therapies for treatment of severe diseases. The company is privately owned and supported by 17 working shareholders with extensive experience from the life science industry.
CPNP has developed an IP-protected process for GMP manufacturing of the NK-cell based drug candidate CellProtect for treatment of multiple myeloma. There is solid preclinical data which show that NK-cells expanded with the patented process has restored cytotoxic activity and ability to selectively kill multiple myeloma cells. CPNP is currently conducting a Phase I trial with CellProtect and awaiting response on a request for Orphan Drug designation in the EU.
CPNP also develops therapies based on other cell types such as mesenchymal stem cells.